Detalhe da pesquisa
1.
An open randomized multicentre Phase 2 trial to assess the safety of DAV132 and its efficacy to protect gut microbiota diversity in hospitalized patients treated with fluoroquinolones.
J Antimicrob Chemother
; 77(4): 1155-1165, 2022 03 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-35016205
2.
Burden of pneumococcal pneumonia requiring ICU admission in France: 1-year prognosis, resources use, and costs.
Crit Care
; 25(1): 24, 2021 01 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33423691
3.
A Panax quinquefolius-Based Preparation Prevents the Impact of 5-FU on Activity/Exploration Behaviors and Not on Cognitive Functions Mitigating Gut Microbiota and Inflammation in Mice.
Cancers (Basel)
; 14(18)2022 Sep 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36139563
4.
Impact of ureido/carboxypenicillin resistance on the prognosis of ventilator-associated pneumonia due to Pseudomonas aeruginosa.
Crit Care
; 15(2): R112, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-21481266
5.
A Colon-Targeted Adsorbent (DAV132) Does Not Affect the Pharmacokinetics of Warfarin or Clonazepam in Healthy Subjects.
Clin Pharmacol Drug Dev
; 10(8): 908-917, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33434399
6.
Clinical Impact of Antifungal Susceptibility, Biofilm Formation and Mannoside Expression of Candida Yeasts on the Outcome of Invasive Candidiasis in ICU: An Ancillary Study on the Prospective AmarCAND2 Cohort.
Front Microbiol
; 9: 2907, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30619103
7.
Dose-finding phase I clinical and pharmacokinetic study of orally administered irinotecan in patients with advanced solid tumors.
Clin Cancer Res
; 12(12): 3774-81, 2006 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-16778105
8.
Targeted adsorption of molecules in the colon with the novel adsorbent-based medicinal product, DAV132: A proof of concept study in healthy subjects.
J Clin Pharmacol
; 55(1): 10-6, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25042595
9.
Evaluation of performance, safety, subject acceptance, and compliance of a disposable autoinjector for subcutaneous injections in healthy volunteers.
Patient Prefer Adherence
; 4: 379-88, 2010 Oct 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-21049090
10.
Resistance to quinupristin-dalfopristin due to mutation of L22 ribosomal protein in Staphylococcus aureus.
Antimicrob Agents Chemother
; 46(7): 2200-7, 2002 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-12069975
11.
Combination of quinupristin-dalfopristin (Synercid) and rifampin is highly synergistic in experimental Staphylococcus aureus joint prosthesis infection.
Antimicrob Agents Chemother
; 46(4): 1122-4, 2002 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-11897604